Phase 1, placebo controlled, randomized study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following single, escalating subcutaneous doses of PF-04603629 in type 2 diabetic adult subjects
Latest Information Update: 08 Nov 2011
At a glance
- Drugs PF 4603629 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 09 Apr 2008 New trial record.